Tissue factor and tissue factor pathway inhibitor.
The classical 'cascade/waterfall' hypothesis formulated to explain in vitro coagulation organised the amplification processes into the intrinsic and extrinsic pathways. Recent molecular biology and clinical data indicate that tissue factor/factor-VII interaction is the primary cellular initiator of coagulation in vivo. The process of blood coagulation is divided into an initiation phase followed by a propagation phase. The discovery of tissue factor pathway inhibitor further supports the revised theory of coagulation. Tissue factor is also a signalling receptor. Recent evidence has shown that blood-borne tissue factor has an important procoagulant function in sepsis, atherosclerosis and cancer, and other functions beyond haemostasis such as immune function and metastases.
Price
G C
GC
Intensive Care Unit, University of New South Wales at St George Hospital, Kogarah, NSW 2217, Australia.
Thompson
S A
SA
Kam
P C A
PC
D000818:Animals; D001777:Blood Coagulation / Q000502:physiology*; D006801:Humans; D008074:Lipoproteins / Q000502:physiology*; D015398:Signal Transduction / Q000502:physiology; D013925:Thromboplastin / Q000502:physiology*; D013927:Thrombosis / Q000503:physiopathology
D008074:Lipoproteins; C051928:lipoprotein-associated coagulation inhibitor; D013925:Thromboplastin